Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Return on Sales: 2018-2025

Historic Return on Sales for Autolus Therapeutics (AUTL) over the last 4 years, with Sep 2025 value amounting to -4.40%.

  • Autolus Therapeutics' Return on Sales fell 1101.00% to -4.40% in Q3 2025 from the same period last year, while for Sep 2025 it was -4.40%, marking a year-over-year decrease of 1101.00%. This contributed to the annual value of -21.80% for FY2024, which is 10092.00% up from last year.
  • Per Autolus Therapeutics' latest filing, its Return on Sales stood at -4.40% for Q3 2025, which was up 62.85% from -11.83% recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Return on Sales peaked at 20.56% during Q4 2024, and registered a low of -142.82% during Q2 2022.
  • Moreover, its 3-year median value for Return on Sales was -0.35% (2023), whereas its average is 3.34%.
  • Its Return on Sales has fluctuated over the past 5 years, first plummeted by 12,180bps in 2021, then surged by 14,247bps in 2023.
  • Quarterly analysis of 5 years shows Autolus Therapeutics' Return on Sales stood at -69.10% in 2021, then slumped by 7,371bps to -0.47% in 2022, then decreased by 3bps to -0.50% in 2023, then spiked by 2,106bps to 20.56% in 2024, then crashed by 1,101bps to -4.40% in 2025.
  • Its Return on Sales stands at -4.40% for Q3 2025, versus -11.83% for Q2 2025 and 20.10% for Q1 2025.